2 active not recruiting, 2 completed, 1 recruiting, 1 terminated. 3 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
Follow RO5126766: new trials by email Literature Review of RO5126766 trials Research Report on RO5126766
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Avutometinib, Biopsy, Biospecimen Collection - Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma | Phase 2 | Recruiting | Emory University | 50 | 2024-07-31 | 2026-04-06 |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma Avutometinib, Biospecimen Collection, Defactinib - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Active not recruiting | Emory University | 14 | 2023-07-28 | 2025-12-15 |
| Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy - Metastatic Uveal Melanoma | Phase 2 | Terminated | Thomas Jefferson University | 13 | 2021-01-26 | 2025-07-15 |
| RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer RO5126766 - Advanced Non-small Cell Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 15 | 2018-10-31 | 2024-07-10 |
| Phase I Trial of Defactinib and VS-6766. VS-6766, Defactinib - NSCLC, Low Grade Serous Ovarian Cancer | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 87 | 2017-12-12 | 2026-03-10 |
| A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors. RO5126766 - Neoplasms | Phase 1 | Completed | Hoffmann-La Roche | 52 | 2008-11-01 | 2016-11-02 |
Adenocarcinoma of Lung (1) · Carcinoma, Endometrioid (1) · Glioblastoma (1) · Lung Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Uveal Melanoma (1)
Emory University (2) · Hoffmann-La Roche (1) · Institute of Cancer Research, United Kingdom (1) · Memorial Sloan Kettering Cancer Center (1) · Thomas Jefferson University (1)
United States (4) · United Kingdom (2) · France (1) · Spain (1)
Conor E Steuer (1) · Gregory Riely, MD, PhD (1) · Kimberly B. Hoang, MD (1) · Rino Seedor, MD (1) · Udai Banerji, FRCP, PhD (1)
PMID 34663687, PMID 37598000, PMID 40579546, PMID 41790275
P30CA138292 (2), 2008 (1), 2017 (1), P01CA257906 (1)